<DOC>
	<DOCNO>NCT01688791</DOCNO>
	<brief_summary>This trial conduct three part . Part A dose escalation trial follow dose confirmation trial folate receptor ( FR ) 100 % endometrial cancer participant . The primary hypothesis trial administration vintafolide combination carboplatin paclitaxel safe tolerable . Part B single dose , dose escalation , pharmacokinetic ( PK ) , QTc interval trial . The primary objective include determination maximum single tolerate dose vintafolide evaluate effect single maximum dose QTc interval . Part C weekly dose escalation trial vintafolide follow dose confirmation . The primary hypothesis part weekly vintafolide acceptable safety tolerability participant advance cancer .</brief_summary>
	<brief_title>A Study MK-8109 ( Vintafolide ) Given Alone With Chemotherapy Participants With Advanced Cancers ( MK-8109-001 )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vinca Alkaloids</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Inclusion criterion participant : Histologicallyconfirmed metastatic locally advanced solid tumor fail respond standard therapy , progress despite standard therapy , standard therapy exist unacceptable participant Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 At least one measurable metastatic recurrent lesion No history previous malignancy exception cervical intraepithelial neoplasia , basal cell carcinoma skin , adequately treat localized prostate carcinoma ; undergone potentially curative therapy evidence disease five year Adequate organ function Female participant childbearing potential must willing use acceptable method birth control abstain heterosexual activity course study 90 day last dose study therapy Male participant must agree use adequate method contraception heterosexual activity start first dose study therapy 90 day last dose study therapy Inclusion criterion Part A : Tumor lesion characterize folate receptor ( FR ) 100 % determine etarfolide Sequential Single Photon Emission Computed Tomography ( SPECT ) CT scan Histologicallyconfirmed diagnosis locally advance metastatic recurrent endometrial cancer Inclusion criterion Parts B &amp; C : Must etarfolatide SPECT/CT scan determine FR status Exclusion criterion participant : Part A &amp; Part C enrol completion Part B : Chemotherapy , radiotherapy , biological therapy ( include monoclonal antibody ) within 4 week prior drug administration , recover adverse event due agent administer 4 week earlier Part B : Chemotherapy , radiotherapy , biological therapy ( include monoclonal antibody ) within 3 week prior drug administration , recover adverse event due agent administer 4 week earlier Currently participate participate study investigational compound device within 28 day initial dose study Part A , dose escalation , Parts B C : More 3 prior cytotoxic regimens metastatic disease . Part A , dose confirmation : Has receive 2 prior cytotoxic regimens metastatic disease . Primary central nervous system ( CNS ) tumor Active CNS metastases and/or carcinomatous meningitis . Known hypersensitivity component study therapy analog Recent ( i.e. , â‰¤ 6 week ) history abdominal surgery peritonitis Bowel occlusion subocclusion Prior whole abdominal whole pelvis radiation therapy radiation therapy &gt; 10 % bone marrow time past prior radiation therapy within last 3 year breast / sternum , head , neck Requires antifolate therapy management comorbid condition Known regular user ( include `` recreational use '' ) illicit drug recent history ( within last year ) drug alcohol abuse Pregnant breastfeeding expect conceive , donate sperm within span study Human Immunodeficiency Virus ( HIV ) positive Active Hepatitis B C Symptomatic ascites pleural effusion . History stem cell bone marrow transplant Exclusion Criteria Part B : Permanent pacemaker Unable refrain use concomitant medication Day 1 Structural heart disease , history myocardial infarction ( MI ) , unstable angina History cardiac arrhythmia , congestive heart failure ( CHF ) , sick sinus syndrome , second third degree atrioventricular ( AV ) block History risk factor Torsades de Pointes CHF , uncorrected hypokalemia , family history long QT syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>